Investigation of a new 1,3-diarylpropenone as a potential antimitotic agent targeting bladder carcinoma

Anti-Cancer Drugs

Volumn 20, Issue 6, 2009, Pages 469-476

  Martel Frachet, Véronique ^a   Areguian, Julie ^b   Blanc, Madeleine ^b   Touquet, Bastien ^a   Lamarca, Arnaud ^a   Ronot, Xavier ^a   Boumendjel, Ahcène ^b  

^a PSL RESEARCH UNIVERSITY   (France)

^b Université Joseph Fourier   (France)

Author keywords

Antimitotics; Bladder carcinoma; Cell cycle; Diarylpropenones

Indexed keywords

1 (2,4 DIMETHOXYPHENYL) 3 (1 METHYLINDOYL)PROPENONE; ANTIMITOTIC AGENT; IPP 51; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROMETAPHASE;

EID: 67249109965     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32832b9fea     Document Type: Article

References (16)

1. Patard JJ, Rodriguez A, Leray E, Rioux-Leclercq N, Guille F, Lobel B. Intravesical Bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours. Eur Urol 2002; 41:635-641. (Pubitemid 35333921)
2. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000; 163:73-78.
3. Ghoneim MA, Abol-Enein H. Management of muscle-invasive bladder cancer: an update. Nat Clin Pract Urol 2008; 5:501-508.
4. Laffaioli RV, Milano A, Caponigro F. Therapy of metastatic bladder carcinoma. Ann Oncol 2007; 18:153-156.
5. Gallagher DJ, Milowsky MI, Bajorin DF. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting. Cancer 2008; 113:1284-1293.
6. Gerby B, Boumendjel A, Blanc M, Bringuier PP, Champelovier P, Fortuné A, et al. 2-Arylidenedihydroindole-3-ones: design, synthesis and biological activity on bladder carcinoma cell lines. Bioorg Med Chem Lett 2007; 17:208-213. (Pubitemid 46001581)
7. Boumendjel A, Boccard J, Carrupt PA, Nicolle E, Blanc M, Geze A, et al. Antimitotic and antiproliferative activities of chalcones: forward structure-activity relationship. J Med Chem 2008; 51:2307-2310.
8. Hendzel MJ, Wei Y, Mancini MA, Van Hooser A, Ranalli T, Brinkley BR, et al. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 1997; 106:348-360. (Pubitemid 27510848)
9. Chang FL, Lai MD. The relationship between p53 status and anticancer drugs-induced apoptosis in nine human bladder cancer cell lines. Anticancer Res 2000; 20:351-355. (Pubitemid 30189778)
10. Chang FL, Lai MD. Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells. J Urol 2001; 166:304-310. (Pubitemid 32565417)
11. Chen JG, Horwitz SB. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. Cancer Res 2002; 62:1935-1938. (Pubitemid 34408432)
12. Lawrence NJ, McGown AT. The chemistry and biology of antimitotic chalcones andrelated enone systems. Curr Pharm Des 2005; 11:1679-1693. (Pubitemid 40668144)
13. Kim do Y, Kim KH, Kim ND, Lee KY, Han CK, Yoon JH, et al. Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin. J Med Chem 2006; 49:5664-5670.
14. Romagnoli R, Baraldi PG, Carrion MD, Cara CL, Cruz-Lopez O, Preti D, et al. Design, synthesis, and biological evaluation of thiophene analogues of chalcones. Bioorg Med Chem 2008; 16:5367-5376. (Pubitemid 351699282)
15. Mollinedo F, Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 2003; 8:413-450.
16. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death bymitotic catastrophe: a molecular definition. Oncogene 2004; 23:2825-2837. (Pubitemid 38638845)